Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effectiveness of the FairCare System for Patients With Advanced Illness
This study has been completed.
Sponsored by: Department of Veterans Affairs
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00105599
  Purpose

This study of the FairCare Program (FC) is designed to address end of life (EOL) care delivery issues by reducing barriers to effective EOL care among health care providers, family members, surrogates, and Chronic Heart Failure (CHF) patients using a comprehensive, multi-pronged approach delivered by a care coordinator and supported by an interdisciplinary team.


Condition Intervention Phase
Terminal Care
Neoplasm
Behavioral: End of life care coordination
Procedure: FairCare System
Phase II

MedlinePlus related topics: Cancer
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title: Effectiveness of the FairCare System for Patients With Advanced Illness

Further study details as provided by Department of Veterans Affairs:

Estimated Enrollment: 140
Study Completion Date: September 2004
Arms Assigned Interventions
1 Behavioral: End of life care coordination Procedure: FairCare System

Detailed Description:

Background:

This study of the FairCare Program (FC) is designed to address end of life (EOL) care delivery issues by reducing barriers to effective EOL care among health care providers, family members, surrogates, and Chronic Heart Failure (CHF) patients using a comprehensive, multi-pronged approach delivered by a care coordinator and supported by an interdisciplinary team.

Objectives:

Evaluate the impact of FC on: 1) improving the quality of life (QOL) and health care delivery for CHF patients with advanced illness, (i.e. ejection fractions of 35% or less, or assessed as level III or IV on the NYS Heart Association Classification System); 2) addressing their fears about dying; 3) increasing their use of Advance Directives (ADs); and 4) improving provider compliance with ADs. Also, describe trends that may occur in disease-specific QOL, survival, and health care use and cost.

Methods:

The study employs a randomized control group design. There are two treatment arms, the FC treatment condition, and the usual care (UC) control condition. Assessments for improving quality of life (QOL), and quality of care delivery are taken at baseline, and at three and six months. Assessments of AD use, i.e. frequency of formulation and documentation of ADs, are taken at baseline, three and six months at one year and 18 months. Because data about compliance with ADs and utilization and cost may not be fully comprehensive until patients' deaths, to maximize the sample size for these variables, and hence the power of the study to detect difference in these outcomes, data on compliance with ADs will be collected in the final year of the study, and data on utilization and cost will be aggregated in monthly intervals and collected from baseline to 18 months. One year of VA pre-intervention health care utilization and cost data will also be collected to assess baseline utilization and to control for any pre-existing differences in the propensity of patients to use health care services. Also, an intention to treat methodology will be used during data analyses.

Status:

The study ends 9-30-04, data for VA cost, Medicare cost, consistency of medical care with patient preferences, and survival, are being collected and analyzed for the final report.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Ejection fraction 35% or less and classification at level 3 or 4 of the New York State Heart Classification System and surrogates of patients meeting this criteria.

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00105599

Locations
United States, New York
Albany VA Medical Center: Samuel S. Stratton
Albany, New York, United States, 12208
Sponsors and Collaborators
Investigators
Principal Investigator: Mollie Shulan, MD Albany VA Medical Center: Samuel S. Stratton
  More Information

Responsible Party: Department of Veterans Affairs ( Shulan, Mollie - Principal Investigator )
Study ID Numbers: CHI 99-071
Study First Received: March 15, 2005
Last Updated: October 31, 2008
ClinicalTrials.gov Identifier: NCT00105599  
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on January 16, 2009